Europe Enteral Nutrition Market is expected to reach US$ 5,797.18 Million by 2031

Nasogastric Segment to Bolster Europe Enteral Nutrition Market Growth During 2023–2031  

According to our new research study on "Europe Enteral Nutrition Market Forecast to 2031 – Regional Analysis – by Product Type," the market was valued at US$ 3,322.95 million in 2023 and is projected to reach US$ 5,797.18 million by 2031; it is anticipated to record a CAGR of 7.2% from 2023 to 2031.

The report emphasizes the Europe enteral nutrition market trends, along with drivers and deterrents affecting the market growth. The surging prevalence of gastrointestinal diseases and increasing cases of malnutrition are contributing to the growing Europe enteral nutrition market size. However, the complications associated with feeding systems hampers the market growth. Further, the development of plant-based nutrition products are expected to emerge as new market trends in the coming years.   

Europe Enteral Nutrition Market Share, by Country, 2023 (%)

Source: The Insight Partners Analysis 

Rising Cases of Malnutrition and Premature Births Favors Enteral Nutrition Market Growth

Undernutrition, overweight or obesity, vitamin or mineral deficiency, and poor diet-related noncommunicable diseases are all categorized under malnutrition. A large number of premature babies suffer from low weight and undeveloped immunity, which puts their lives at risk. Most medical guidelines advise enteral nutrition for supporting the optimal growth of preterm infants if they are unable to drink, suck, swallow, and breathe. As per the study "The situation and the challenges with regard to preterm birth in Europe,” 1 in 10 newborns (i.e., ~500,000 babies) is premature in Europe every year; the number of preterm babies is expected to rise in the coming years as well. Nutritional support can be delivered through enteral means, depending on the need, which is an essential and appropriate way of treating most premature birth cases. Thus, the massive burden of malnutrition in patients from different age groups and the increasing number of premature births drive the demand for enteral nutrition formulae and products in Europe.

Europe Enteral Nutrition Market Report Scope:

Based on product type, the enteral nutrition market is segmented into nasogastric, nasoenteral, sipping, and others. The nasogastric segment held the largest enteral nutrition market share in 2023. Nasogastric feeding involves the insertion of a small tube into the stomach through the nose, offering a simple, cost-effective solution for providing nutrition to patients facing swallowing difficulties, neurological disorders, or severe conditions that impair oral intake. Diabetes often leads to malnutrition and increases the need for enteral feeding formulas. As per the World Health Organization (WHO), diabetes is among the common chronic conditions in the WHO European Region, and Europe has the highest burden of Type 1 diabetes in the world. WHO estimated that 1 in 10 people living in the Region will have diabetes by 2045.

The nasogastric segment is further segmented into standard and disease specific. Standard formulas provide basic nutritional support for patients who are unable to consume food orally. Standard enteral nutrition formulas provide a balance of macronutrients (carbohydrates, protein, and fats), micronutrients (vitamins and minerals), and fibers, depending on the specifications. These formulas provide 10–25% energy from protein sources, including milk, whey, casein, caseinates, or soy protein. The standard segment held a larger market share in 2023; further, the disease specific segment is likely to witness a faster growth rate during the forecast period. Standard feeding formulas are typically well tolerated irrespective of complete protein and long-chain fatty acid content. Calorically dense formulas (1.5–2.0 kcal/ml) are usually required to provide adequate energy. These are intended and recommended for patients who require nutrition to maintain health and who suffer from digestion problems. Nestlé and Abbott are among the companies offering standard protein enteral feeding formulations. Jevity 1.0 Cal, manufactured by Abbott, is composed of milk and soy protein. It is a standard protein product containing fibers and is suitable for lactose-intolerant people. Further, general or standard nutrition formulas may not be precise in providing patients with the quantities of nutrients required for the body to function correctly. Therefore, doctors prescribe nutrition products specific to diseases. For example, renal formulas are more calorically dense and contain lower concentrations of phosphorous, potassium, and magnesium than standard formulas. Similarly, pulmonary formulas feature less carbohydrate content than standard formulas. Pharmaceutical companies provide enteral nutrition with tailored constituents (patient-specific) to meet individual patient needs. For example, Impact (offered by Nestle) is a clinically proven nutritional solution for managing primary elective surgery patients to reduce postoperative complications and length of hospital stays.

Europe Enteral Nutrition Market Analysis: Based on Country

The scope of the Europe enteral nutrition market report includes the assessment of the market performance in the UK, Germany, France, Italy, Spain, Czech Republic, and the Rest of Europe. Germany is the largest contributor to the Europe enteral nutrition market growth. Nutritional deficiencies lead to unfavorable outcomes and a lower quality of life in patients with malignancies. Patients with active tumors often suffer due to the insufficient intake of food. The therapeutic objectives of enteral nutrition include the prevention or reduction of progressive weight loss. According to the Association of the Scientific Medical Societies in Germany, patients with severe gastrointestinal defects such as radiation enteritis need enteral nutrition to meet their nutrient requirements. In most cases, artificial nutrition stabilizes or increases body weight and body fat mass. As per the "World Population Ageing," nearly 28.0% of the total population of Germany was aged 60 or more in 2017, and it is estimated to rise to nearly 37.6% by 2050. As people age, they often face a variety of health issues that can lead to malnutrition or difficulties in eating. Population aging generates a significant demand for enteral nutrition.

The increasing prevalence of chronic diseases such as cancer, diabetes, and neurological disorders propels the demand for enteral nutrition. According to the International Diabetes Federation, the diabetes prevalence rate in Germany was 10% in 2022. As per the Deutsches Zentrum für Diabetesforschung (DZD), ~8.5 million people had diabetes as of 2022, and approximately 2 million people had undiagnosed diabetes. Diabetes often leads to malnutrition or the need for enteral feeding.

The Servona Group is among the top manufacturers of medical products, medical aids, and complete home care providers in Germany. It offers enteral nutrition products and feeding pumps. According to the company, ~120,000 patients in Germany rely on enteral nutrition. According to an article published in the National Center for Biotechnology Information in August 2009, German statutory and private health insurance policies provide coverage for enteral nutrition products. As a result, approximately 100,000 patients receive reimbursement for their enteral nutrition products. Nearly 70% of the patients are tube-fed for an average period of 9 months. Further, ~70% of tube-fed patients receive care in institutions and ~30% at home. The stats indicate an increase in the demand for enteral nutrition formulas in Germany.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com